Century Therapeutics (IPSC) Stock Overview
A biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IPSC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Century Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.25 |
| 52 Week High | US$3.04 |
| 52 Week Low | US$0.43 |
| Beta | 1.67 |
| 1 Month Change | -3.85% |
| 3 Month Change | 10.29% |
| 1 Year Change | 368.75% |
| 3 Year Change | -27.65% |
| 5 Year Change | n/a |
| Change since IPO | -90.14% |
Recent News & Updates
Recent updates
There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise
Dec 17
We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Nov 30There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding
Oct 08Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101
Jun 20Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely
Mar 06Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy
Feb 01We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Oct 23Century Therapeutics receives IND clearance for allogeneic cell therapy candidate
Aug 25Shareholder Returns
| IPSC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.6% | -0.2% | 3.3% |
| 1Y | 368.8% | 40.4% | 28.1% |
Return vs Industry: IPSC exceeded the US Biotechs industry which returned 40.4% over the past year.
Return vs Market: IPSC exceeded the US Market which returned 28.1% over the past year.
Price Volatility
| IPSC volatility | |
|---|---|
| IPSC Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: IPSC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IPSC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 78 | Brent Pfeiffenberger | www.centurytx.com |
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases.
Century Therapeutics, Inc. Fundamentals Summary
| IPSC fundamental statistics | |
|---|---|
| Market cap | US$404.38m |
| Earnings (TTM) | -US$9.58m |
| Revenue (TTM) | US$109.16m |
Is IPSC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPSC income statement (TTM) | |
|---|---|
| Revenue | US$109.16m |
| Cost of Revenue | US$95.67m |
| Gross Profit | US$13.50m |
| Other Expenses | US$23.08m |
| Earnings | -US$9.58m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.053 |
| Gross Margin | 12.36% |
| Net Profit Margin | -8.78% |
| Debt/Equity Ratio | 0% |
How did IPSC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/12 03:42 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Century Therapeutics, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Chen Yang | BofA Global Research |
| William Maughan | Canaccord Genuity |